Risk model based on routine blood work predicts treatment response and survival of metastatic cancer patients treated with immune checkpoint inhibitors. A risk model developed by researchers can help to identify cancer patients who could benefit from immune checkpoint inhibitors, ICIs. Published in BMC Cancer, the study was conducted at the University of Eastern Finland […]
Read More… from Risk Model Predicts Response and Survival in Metastatic Cancer Patients